The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease
Abstract
Several beneficial effects of resveratrol (RES), a natural antioxidant present in red wine have already been described. The aim of our study was to investigate if RES had a clinically measurable cardioprotective effect in patients after myocardial infarction. In this double-blind, placebo controlled trial 40 post-infarction Caucasian patients were randomized into two groups. One group received 10 mg RES capsule daily for 3 months. Systolic and diastolic left ventricular function, flow-mediated vasodilation (FMD), several laboratory and hemorheological parameters were measured before and after the treatment. Left ventricular ejection fraction showed an increasing tendency (ns) by RES treatment. However, left ventricular diastolic function was improved significantly (p < 0.01) by RES. A significant improvement in endothelial function measured by FMD was also observed (p < 0.05). Low-density lipoprotein (LDL) level significantly decreased (p < 0.05) in the RES treated group. Red blood cell deformability decreased and platelet aggregation increased significantly in the placebo group (p < 0.05), while resveratrol treatment has prevented these unfavourable changes. Concerning other measured parameters no significant changes were observed neither in placebo nor in RES group. Our results show that resveratrol improved left ventricle diastolic function, endothelial function, lowered LDL-cholesterol level and protected against unfavourable hemorheological changes measured in patients with coronary artery disease (CAD).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
Celermajer, D. S., Sorensen, K. E., Gooch, V. M., Spiegelhalter, D. J., Miller, O. I., Sullivan, I. D., Lloyd, J. K., & Deanfield, J. E. (1992) · The Lancet · doi:10.1016/0140-6736(92)93147-f · Cited by 4,742
Therapeutic potential of resveratrol: the in vivo evidence
Baur, J. A., & Sinclair, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2060 · Cited by 3,958
Schächinger, V., Britten, M. B., & Zeiher, A. M. (2000) · Circulation · doi:10.1161/01.cir.101.16.1899 · Cited by 2,585
Wallerath, T., Deckert, G., Ternes, T., Anderson, H., Li, H., Witte, K., & Förstermann, U. (2002) · Circulation · doi:10.1161/01.cir.0000029925.18593.5c · Cited by 666
Stein, J. H., Keevil, J. G., Wiebe, D. A., Aeschlimann, S., & Folts, J. D. (1999) · Circulation · doi:10.1161/01.cir.100.10.1050 · Cited by 578
Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes
Hung, L. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00102-4 · Cited by 541
Anti-Inflammatory Responses of Resveratrol
Das, S., & Das, D. (2007) · Inflammation & Allergy-Drug Targets · doi:10.2174/187152807781696464 · Cited by 382
Wines and grape juices as modulators of platelet aggregation in healthy human subjects
Pace-Asciak, C. R., Rounova, O., Hahn, S. E., Diamandis, E. P., & Goldberg, D. M. (1996) · Clinica Chimica Acta · doi:10.1016/0009-8981(96)06236-5 · Cited by 316
Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol
Olson, E. R., Naugle, J. E., Zhang, X., Bomser, J. A., & Meszaros, J. G. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00763.2004 · Cited by 173
Wang, Z., Zou, J., Cao, K., Hsieh, T., Huang, Y., & WU, J. M. (2005) · PubMed · Cited by 152
Cited by
The therapeutic potential of resveratrol: a review of clinical trials
Berman, A. Y., Motechin, R. A., Wiesenfeld, M. Y., & Holz, M. K. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0038-6 · Cited by 888
Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds
Bonkowski, M. S., & Sinclair, D. A. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.93 · Cited by 834
Mitochondrial function as a therapeutic target in heart failure
Brown, D. A., Perry, J. B., Allen, M. E., Sabbah, H. N., Stauffer, B. L., Shaikh, S. R., Cleland, J. G. F., Colucci, W. S., Butler, J., Voors, A. A., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.203 · Cited by 803
Phenolic compounds: Current industrial applications, limitations and future challenges
Albuquerque, B. R., Heleno, S. A., Oliveira, M. B. P. P., Barros, L., & Ferreira, I. C. F. R. (2021) · Food & Function · doi:10.1039/d0fo02324h · Cited by 716
Potential Adverse Effects of Resveratrol: A Literature Review
Shaito, A., Posadino, A. M., Younes, N., Hasan, H., Halabi, S., Alhababi, D., Al-Mohannadi, A., Abdel-Rahman, W. M., Eid, A. H., Nasrallah, G. K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062084 · Cited by 716
Metadata
- Authors
- Magyar, K., Halmosi, R., Palfi, A., Feher, G., Czopf, L., Fulop, A., Battyany, I., Sumegi, B., Toth, K., & Szabados, E.
- Venue
- Clinical Hemorheology and Microcirculation
- Publisher
- SAGE Publications
- Published
- 2012
- Volume
- 50
- Issue
- 3
- Pages
- 179-187
- ISSN
- 1386-0291 (ISSN-L)
- OpenAlex
- W1606511543
- Cited by
- 364
- References
- 21
- FWCI
- 11.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. https://app.cochat.ai/papers/10.3233/ch-2011-1424
- The paper
- Magyar, K., Halmosi, R., Palfi, A., Feher, G., Czopf, L., Fulop, A., Battyany, I., Sumegi, B., Toth, K., & Szabados, E. (2012). Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clinical Hemorheology and Microcirculation. https://doi.org/10.3233/ch-2011-1424
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
